Specify the programme decision
Connect the biological endpoint to a defined stage, therapeutic question and action.
For pharma, biotech and CRO teams
JetBio manufactures and sells configurable 3D bioprinting systems with control software, installation, training and application support. We work from a defined drug-development question towards a fit-for-purpose model and reproducible workflow.

A decision-led starting point
The same model cannot answer every discovery, efficacy or safety question. A credible programme states where the model will be used, what it will measure and what decision its output may inform.
Connect the biological endpoint to a defined stage, therapeutic question and action.
Select cells, materials, architecture and culture conditions around the biology that matters.
Include operators, formats, throughput, controls, readouts and transfer requirements in the development brief.

Applications-led modularity
JetBio supplies one supported system with reactive jet impingement, microvalve and inkjet development modes. The configured workflow may use one mode or combine complementary capabilities, subject to material compatibility and the required model architecture.
Evidence requirements
The ABPI and NC3Rs identify robustness, validation, standardisation and scalability as central gaps between promising academic models and routine pharmaceutical use. JetBio does not represent research deployments as qualified drug-development tools.
Read the ABPI and NC3Rs landscape reviewCommercial pathway
Align on therapeutic area, programme stage, current model and decision need.
Define materials, format, comparator, controls, evidence gates, responsibilities and commercial terms.
Generate relevant evidence against a bounded work package and record limitations as well as results.
Review the evidence and operational fit, then agree the system configuration, software workflow, installation, training and support.
Frequently asked questions
Potential uses include disease-model development, target and mechanism research, assay development and selected safety or efficacy studies. The relevant use must be defined for each programme rather than assumed from the technology alone.
No. Human-relevant in vitro models may reduce or replace animal use in defined contexts, but that requires suitable evidence, validation and, where applicable, regulatory engagement. JetBio does not make a blanket replacement claim.
Selected multiwell workflows form part of the development pathway. Required plate format, replicate number, handling, readout and automation interfaces must be assessed during scoping.
The usual starting point is a confidential fit discussion followed, where appropriate, by a scoped feasibility or application-development project with agreed evidence gates.
Enquiry form
Share the context of use, current model, readout, format, throughput and evidence threshold for a confidential fit review.
Please do not include confidential, personal health or unpublished research data.
Start a useful conversation
Review the modular architecture, software and support offer, then define the evidence needed for a procurement decision.